Taking people in ChinaEarly phase 1

Tests CD70 CAR T-cell treatment in blood cancers with CD70 protein

Tests CD70 CAR T-cells in people with CD70-positive leukemia, lymphoma or myeloma.

Plain-language title generated from the registry record
Registry title: CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

Key facts

Where: Hangzhou, ChinaSee the site
Phase: Early phase 1

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people whose blood cancer (acute myeloid leukemia, non-Hodgkin lymphoma or multiple myeloma) has CD70 and has come back or did not respond to treatment. They would receive CD70 CAR T-cells.

Age: No age limit is stated for non-Hodgkin lymphoma and multiple myeloma. No age range is given for acute myeloid leukemia.
Sex: All sexes can join.
Disease stage: Relapsed or refractory CD70-positive disease. Acute myeloid leukemia: no remission after chemotherapy, remission shorter than 12 months, or 2 or more relapses. Non-Hodgkin lymphoma: no response or relapse after second-line or later chemotherapy, primary drug resistance, or relapse after auto-HSCT. Multiple myeloma: relapsed or refractory disease, or positive minimal residual disease, or a lesion outside the bone marrow that chemotherapy or radiotherapy can hardly remove.
Earlier treatment: Must have had earlier treatment that did not work or stopped working. Cannot have had any CAR-T or other genetically modified T-cell therapy before. Cannot have had systemic steroids within 2 weeks before screening.
Biomarker or test result: The cancer must be CD70-positive.

Main reasons for not taking part

Pregnant or breastfeeding women
Active hepatitis B or hepatitis C infection, or HIV infection
Severe active infection
Serious heart problems, such as a prolonged QT interval or severe arrhythmia
History of head injury, epilepsy, or brain blood vessel disease

Read by machine on 12 November 2026.

Where in China

The first affiliated hospital of medical college of zhejiang universityHangzhou, ChinaContact: He Huang, MDTaking people

Questions to ask the study team

How often do I need to come in, and for how long each time?
Are travel costs paid?
Can I keep my own doctor?
What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it: Zhejiang University
Trial code: NCT04662294
Record updated: 4 November 2021
Original description: A Study of CD 70 CAR T for patients with CD70 positive malignant hematologic diseasesRead full original descriptionShow less
Clinical Trial for the Safety and Efficacy of CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
A Study of CD 70 CAR T for patients with CD70 positive malignant hematologic diseases
Inclusion: Histologically confirmed diagnosis of CD70 AML per the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Myeloid Leukemia (2016.v1); Relapsed or refractory CD70+ AML (meeting one of the following conditions):; CR not achieved after standardized chemotherapy; CR achieved following the first induction, but CR duration is less than 12 months; Ineffectively after first or multiple remedial treatments; 2 or more relapses; The number of primordial cells in bone marrow is > 5% (by morphology), and/or > 0.01% (by flowcytometry); Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit ofnormal, creatinine ≤ 176.8 umol/L; Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%; No active infection in the lungs, blood oxygen saturation in indoorair is ≥ 92%; Estimated survival time ≥ 3 months; ECOG performance status 0 to 2; Patients or their legal guardians volunteer to participate in the studyand sign the informed consent; No gender and age limit; Histologically confirmed diagnosis of DLBCL (NOS), FL, DLBCL transformed from CLL/SLL, PMBCL, and HGBCL per the WHO Classification Criteria for Lymphoma (2016); Relapsed or refractory CD70+ NHL (meeting one of the following conditions):; No response or relapse after second-line or above chemotherapy regimens; Primary drug resistance; Relapse after auto-HSCT; At least one assessable tumor lesion per Lugano 2014 criteria; Histologically confirmed diagnosis of CD70 multiple myeloma (MM)：; According to the diagnostic criteria of IMWG multiple myeloma, the diagnosis was recurrent / refractory multiple myeloma; Cases with recurrent positive minimal residual disease; Extramedullary leision which is hard to be eradicated by chemotherapy or radiotherapy; No gender and age limit; Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8 umol/L; Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%; No active infection in the lungs, blood oxygen saturation in indoorair is ≥ 92%; Estimated survival time ≥ 3 months; ECOG performance status 0 to 2; Patients or their legal guardians volunteer to participate in the studyand sign the informed consent; Common inclusion criteria :; Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8 umol/L; Echocardiogram shows left ventricular ejection fraction (LVEF) ≥ 50%; No active infection in the lungs, blood oxygen saturation in indoor air is ≥ 92%; Estimated survival time ≥ 3 months; ECOG performance status 0 to 2; Patients or their legal guardians volunteer to participate in the study and sign the informed consent -.
Exclusion: Concurrent therapy with systemic steroids within 2 weeks prior to screening, except for the patients recently or currently receiving inhaled steroids; Previously treated with any CAR-T cell product or other geneticallymodified T cell therapies; History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic diseases; Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis); Active infection of hepatitis B virus or hepatitis C virus; Other uncontrolled diseases that were not suitable for this trial; Patients with HIV infection; Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past; Creatinine >2.5mg/dl, or ALT / AST>3 times of normal amounts, or bilirubin>2.0 mg/dl; Pregnant (or lactating) women; Any situations that the investigator believes may increase the risk of patients or interfere with the results of study. -.
ClinicalTrials.gov NCT04662294